

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: June 24, 2009

Signature: /David A. Gass #38,153/
(David A. Gass)

Docket No.: 28967/34891.1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kari Alitalo et al.

Application No.: 10/774,802

Confirmation No.: 9059

Filed: February 9, 2004

Art Unit: 1647

Title: (As amended herein) THERAPY TARGETING
FLT4 (VEGFR-3) EXPRESSED IN BLOOD
VESSELS

Examiner: Ian Dang

AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

INTRODUCTORY COMMENTS

This paper is timely filed in response to an Office Action dated March 24, 2009, in this matter. Reconsideration is respectfully requested in view of the amendments and remarks that follow.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks/Arguments begin on page 22 of this paper.

A Rule 132 declaration from Dr. Sirpa Jalkanen (together with appendices referred to in the declaration) is appended hereto as part of Applicants response. A copy of the Board's Decision *Ex Parte Engel and Diserod* also is appended hereto.